新冠与接种及未接种人群中的精神疾病
结果显示各队列新冠后1-4周多数精神疾病发病率升高,接种队列升幅低于疫苗前可用与未接种队列;住院新冠后升幅更高且持续更久。
要点
- 新冠诊断后1-4周内多数精神疾病发病率升高,接种队列升幅低于未接种与疫苗前可用队列。
- 接种队列新冠后1-4周抑郁与严重精神疾病的aHR分别为1.16与0.91,未接种队列分别为1.79与1.45。
- 新冠住院后精神疾病发病率升幅更高且持续更久,未接种者中可持续至一年。
核心结论
- 在未接种人群中,重症新冠后精神疾病发病率升高可持续至一年。
- 这些发现提示接种可能减轻新冠对心理健康的不良影响。
研究设计与样本
- 研究在3个队列中进行:1个疫苗可用前队列(2020年1月至2021年6月,野生型/Alpha变异株时期)和2个(接种与未接种)Delta变异株时期队列(2021年6月至12月)。
- 纳入在英格兰全科医生处注册至少6个月、基线时存活且年龄18至110岁已知、性别、剥夺指数信息与地区已知者,排除基线前已有新冠者;数据分析时间为2022年7月至2024年6月。
- 最大队列为疫苗可用前队列,纳入18 648 606人(女性9 363 710人[50.2%],男性9 284 896人[49.8%]),中位(IQR)年龄49(34-64)岁。
- 接种队列纳入14 035 286人(女性7 308 556人[52.1%],男性6 726 730人[47.9%]),中位(IQR)年龄53(38-67)岁;未接种队列纳入3 242 215人(女性1 363 401人[42.1%],男性1 878 814人[57.9%]),中位(IQR)年龄35(27-46)岁。
主要发现
- 各队列中,新冠诊断后第1至4周多数结局的发病率较新冠前或无新冠时升高。
- 疫苗可用前队列新冠后第1至4周抑郁与严重精神疾病的aHR分别为1.93(95%CI 1.88-1.98)与1.49(95%CI 1.41-1.57)。
- 未接种队列新冠后第1至4周抑郁与严重精神疾病的aHR分别为1.79(95%CI 1.68-1.90)与1.45(95%CI 1.27-1.65)。
- 接种队列新冠后第1至4周抑郁与严重精神疾病的aHR分别为1.16(95%CI 1.12-1.20)与0.91(95%CI 0.85-0.98)。
- 新冠住院后发病率升幅更高且持续更久。
关键数值与推荐
- 暴露为记录于初级保健、二级保健、检测数据或死亡登记中的确诊新冠诊断。
- 主要结局指标为抑郁、严重精神疾病、广泛性焦虑、创伤后应激障碍、进食障碍、成瘾、自伤与自杀,比较新冠诊断后与新冠前或无新冠时的发病率,采用调整后风险比(aHR)。
- 新冠后第1至4周抑郁aHR:疫苗可用前队列1.93(95%CI 1.88-1.98),未接种队列1.79(95%CI 1.68-1.90),接种队列1.16(95%CI 1.12-1.20)。
- 新冠后第1至4周严重精神疾病aHR:疫苗可用前队列1.49(95%CI 1.41-1.57),未接种队列1.45(95%CI 1.27-1.65),接种队列0.91(95%CI 0.85-0.98)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Associations have been found between COVID-19 and subsequent mental illness in both hospital- and population-based studies. However, evidence regarding which mental illnesses are associated with COVID-19 by vaccination status in these populations is limited. OBJECTIVE: To determine which mental illnesses are associated with diagnosed COVID-19 by vaccination status in both hospitalized patients and the general population. DESIGN, SETTING, AND PARTICIPANTS: This study was conducted in 3 cohorts, 1 before vaccine availability followed during the wild-type/Alpha variant eras (January 2020-June 2021) and 2 (vaccinated and unvaccinated) during the Delta variant era (June-December 2021). With National Health Service England approval, OpenSAFELY-TPP was used to access linked data from 24 million people registered with general practices in England using TPP SystmOne. People registered with a GP in England for at least 6 months and alive with known age between 18 and 110 years, sex, deprivation index information, and region at baseline were included. People were excluded if they had COVID-19 before baseline. Data were analyzed from July 2022 to June 2024. EXPOSURE: Confirmed COVID-19 diagnosis recorded in primary care secondary care, testing data, or the death registry. MAIN OUTCOMES AND MEASURES: Adjusted hazard ratios (aHRs) comparing the incidence of mental illnesses after diagnosis of COVID-19 with the incidence before or without COVID-19 for depression, serious mental illness, general anxiety, posttraumatic stress disorder, eating disorders, addiction, self-harm, and suicide. RESULTS: The largest cohort, the pre-vaccine availability cohort, included 18 648 606 people (9 363 710 [50.2%] female and 9 284 896 [49.8%] male) with a median (IQR) age of 49 (34-64) years. The vaccinated cohort included 14 035 286 individuals (7 308 556 [52.1%] female and 6 726 730 [47.9%] male) with a median (IQR) age of 53 (38-67) years. The unvaccinated cohort included 3 242 215 individuals (1 363 401 [42.1%] female and 1 878 814 [57.9%] male) with a median (IQR) age of 35 (27-46) years. Incidence of most outcomes was elevated during weeks 1 through 4 after COVID-19 diagnosis, compared with before or without COVID-19, in each cohort. Incidence of mental illnesses was lower in the vaccinated cohort compared with the pre-vaccine availability and unvaccinated cohorts: aHRs for depression and serious mental illness during weeks 1 through 4 after COVID-19 were 1.93 (95% CI, 1.88-1.98) and 1.49 (95% CI, 1.41-1.57) in the pre-vaccine availability cohort and 1.79 (95% CI, 1.68-1.90) and 1.45 (95% CI, 1.27-1.65) in the unvaccinated cohort compared with 1.16 (95% CI, 1.12-1.20) and 0.91 (95% CI, 0.85-0.98) in the vaccinated cohort. Elevation in incidence was higher and persisted longer after hospitalization for COVID-19. CONCLUSIONS AND RELEVANCE: In this study, incidence of mental illnesses was elevated for up to a year following severe COVID-19 in unvaccinated people. These findings suggest that vaccination may mitigate the adverse effects of COVID-19 on mental health.
引用
- Walker VM, Patalay P, Cuitun Coronado JI, et al. COVID-19 and Mental Illnesses in Vaccinated and Unvaccinated People. JAMA Psychiatry. 2024. PMID: 39167370. doi:10.1001/jamapsychiatry.2024.2339
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。